Oxygen therapy is the use of oxygen as medical intervention to maintain enough oxygen in conditions such as hypoxia, hypoxemia, and other related conditions. Oxygen may be administered through a nasal cannula, face mask, or through hyperbaric oxygen chamber. This therapy helps maintain oxygen level in the blood for treatment of acute and chronic diseases such as chronic obstructive diseases (COPD), pneumonia, and asthma. Long-term therapy with oxygen is often useful in people suffering from COPD. Certain other acute or chronic disease conditions where oxygen therapy is effective include cystic fibrosis, dysplasia, heart failure, sleep apnea, and lung disorders.
Download the PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/97
Increasing incidence of COPD and lung disorders drive growth of the oxygen therapy market across the globe
Factors such as high prevalence of respiratory related diseases, growing aging population, and increasing vulnerability of the populace to respiratory conditions are fueling growth of the oxygen therapy market in North America. According to the Center for Diseases Control and Prevention (CDC), around 15.7 million people in the U.S. were diagnosed with COPD in 2013. Other factors driving demand for oxygen therapy include innovation in portable oxygen concentrators, rise in number of untreated sleep apnea cases, favorable reimbursement scenario, growing demand for oxygen filling devices, good medical facilities, and high investment in research and development activities. The European market in oxygen therapy is also gaining traction in recent times, mainly fueled by increasing number of patients suffering from respiratory diseases and favorable government initiatives to facilitate respiratory care.
Global players engaged in the oxygen therapy market
There are several medical device companies, both local player and global ones, engaged in manufacture of oxygen therapy devices. Some of the prominent players are Respironics, Inc. (a Philips company), Fisher & Paykel Healthcare Limited, Teleflex Incorporated, Invacare Corporation, AirSep Corporation, CareFusion Corporation, DeVilbiss Healthcare, MAQUET Holding B.V. & Co. KG, and ResMed, Inc.
According to the World Health Organization, over 90% of COPD deaths occur in low income and middle income countries. Therefore, the oxygen therapy market is expected to grow substantially in African, Asian, and Latin American countries due to high prevalence of COPD and deaths due to the disease. Furthermore, increasing awareness among medical facilities, increasing government investment in healthcare facilities, and availability of low cost treatment is projected to drive demand for oxygen therapy in emerging economies.
Alarming increase in number of lung damage cases increasing demand for oxygen therapy for effective treatment
According to World Health Organization (WHO) over 3 million people die each year due to COPD. Increasing use of oxygen therapy in treatment of diseases such as COPD, asthma, obstructive sleep apnea, and respiratory distress syndrome is a supportive prevalent trend in the market. Long-term oxygen therapy for patients suffering from chronic lung disease can help improve quality and length of life, in turn creating a favorable environment for the market. Increasing risk of lung damage due to tobacco consumption, occupational hazards, and pollution would further augment market growth over the following decade. Click to Read More On Oxygen Therapy Market